Načítá se...
As Technologies for Nucleotide Therapeutics Mature, Products Emerge
The long path from initial research on oligonucleotide therapies to approval of antisense products is not unfamiliar. This lag resembles those encountered with monoclonal antibodies, gene therapies, and many biological targets and is consistent with studies of innovation showing that technology matu...
Uloženo v:
| Vydáno v: | Mol Ther Nucleic Acids |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Gene & Cell Therapy
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5686430/ https://ncbi.nlm.nih.gov/pubmed/29246316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtn.2017.10.017 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|